ArticlePloS one2025
Idiopathic epiretinal membrane area changes in eyes with good vision and the association with visual function.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Functional Biomarkers of Idiopathic Epiretinal Membrane Progression: A 24-Month Prospective Observational Study.Investigative ophthalmology & visual science · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate idiopathic epiretinal membrane (iERM) area changes and the association with visual function in patients with good vision, using confocal scanning laser ophthalmoscopy (cSLO).
methodsThe medical records of patients with iERM with best-corrected visual acuity (BCVA) ≥ 20/25 and a follow-up period ≥ 2 years were reviewed retrospectively. BCVA, metamorphopsia, fundus images using cSLO, and optical coherence tomography images were obtained at baseline and every 6 months. The ERM area and diagonal lengths of the long and short axes were determined. The progression group was defined as eyes with ≥2 lines of loss, and the stable group was defined as eyes with less change.
resultsThis study included 46 eyes, with 23 eyes in each group. Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. In the progression group, BCVA reduction was correlated with area decrease (β = 0.571, P = 0.010). No factors were associated with metamorphopsia. In the univariate analysis, ERM area reduction at 6 months was a significant predictor of vision loss (odds ratio, 1.632; P = 0.002). Receiver operating characteristic analysis identified a 7.66% ERM area reduction at 6 months as the optimal cutoff for predicting vision loss (81.8% sensitivity, 82.6% specificity).
conclusionsERM area reduction significantly correlates with vision loss in patients with iERM with good vision. Monitoring ERM area changes can help predict disease progression and visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.